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PARKINSON’S DISEASE IS A COMMON
HEALTH CARE PROBLEMWITH
SIGNIFICANT SOCIAL AND ECONOMIC
IMPLICATIONS
More than one million people in the
US (five million people worldwide) are
believed to have Parkinson’s disease, and
its prevalence is expected to double by 2030
(1). The national annual economic burden
for Parkinson’s disease in 2010 was esti-
mated at more than $14.4B and is expected
to grow substantially due to the increas-
ing aging population (2). Disease preva-
lence is age-associated, with approximately
1–2% of the population being affected
at 65 years (3). The cardinal clinical fea-
tures of Parkinson’s disease are tremor,
bradykinesia, rigidity, and postural insta-
bility (4). Parkinson’s disease significantly
affects employability and activities of daily
living, leading to a reduction in health-
related quality of life and increases in mor-
bidity and mortality (5, 6). Parkinson’s dis-
ease has a substantial impact on patients,
caregivers, and the healthcare system, espe-
cially as the disease progresses and patients
are less able to care for themselves (7).
While l-DOPA has resulted in signif-
icant improvement in quality of life and
reduction in Parkinson’s disease-related
mortality (8), a number of motor com-
plications develop in approximately 50%
of patients within 3–5 years (9). The most
common l-DOPA-induced motor com-
plications include motor fluctuations
(e.g., wearing off, unpredictable “off–
on” fluctuations) and dyskinesia can be
more disabling than the motor symp-
toms for which treatment was initiated
(10). Wearing off applies to rapid reduc-
tion in mobility; dyskinesia is expressed
as dance-like, random involuntary move-
ments, classified as chorea (typically when
“on”) or dystonia (typically when “off”)
(11). The pathogenesis of these changes is
not well understood (12). These motor
fluctuations and dyskinesia are man-
aged with dose adjustment of l-DOPA
and/or the co-administration of adjunc-
tive therapies (dopamine agonists, MAO-B
inhibitors, or amantadine). To design an
appropriate management plan, specialized
evaluation is needed. However, access to
such care has become increasingly difficult.
The most recent WHO atlas of resources
for neurological disorders indicates that the
lack of access to specialists varies from 0.03
to 4.84 per 100,000 population depending
on geographic location (13).
PHARMACOTHERAPEUTIC
ADJUSTMENTS REQUIRE IN-OFFICE
CLINICAL EVALUATION AND
INTERPRETATION OF
PATIENT-REPORTED DATA
To appreciate the magnitude of motor
deficits, a full neurological examination
is required. The quantification of such
deficits is often made using a clinical scale,
the motor part of the Unified Parkinson’s
Disease Rating Scale (UPDRS, or MDS-
UPDRS) (14, 15). This scale provides clin-
icians with an opportunity to rate each
motor domain (e.g., tremor, bradykinesia,
rigidity, etc.) with an integer score ranging
from 0 to 4 in graded severity. For the man-
agement of l-DOPA-induced motor com-
plications, medical decisions are typically
“empirical,” based on patient narratives
about their experiences between visits or
less frequently by a patient pen-and-paper
diary. The latter requires patients’ input
every 30 min in a complex time matrix.
Reduced compliance and recall bias signif-
icantly limit the real-world utility of the
diary in its current form (16). In clini-
cal trial settings, it has been demonstrated
that close patient monitoring and treat-
ment “optimization” can lead to signifi-
cant improvement of motor function and
fluctuations even before administration of
experimental interventions (17).
In summary, challenges related with
current practices in management of
Parkinson’s disease patients are: (1) infre-
quent visits and problematic access to
specialists (2) inadequate monitoring of
between-visit function, and (3) poor treat-
ment optimization due to insufficient
patient data. Patients may also delay or
avoid chronic disease management services
because they are costly, time-consuming,
and difficult to come by as physicians’
time is increasingly constrained. As a result,
patients’ functional state can be subopti-
mal and may lead to unnecessary eval-
uations in the emergency room and at
times even costly interventions, all of
which have the unintended consequence
of increasing health resource utilization.
In this scenario, user-friendly instruments
for measuring motor function and mon-
itoring treatment-induced motor compli-
cations in the home setting could revolu-
tionize access to care and enhance treat-
ment optimization with currently available
drugs.
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QUANTITATIVE PORTABLE
MEASUREMENTS ARE EASIER TO
ADMINISTER AND MAY REDUCE THE
NEED FOR IN-CLINIC VISITS
Unlike clinical rating scales that uti-
lize categorical ratings, objective symptom
monitoring can quantify motor scores on
a continuum, allowing for greater preci-
sion in recording subtle changes in Parkin-
son’s disease motor symptomatology (16).
Several studies have demonstrated that
remote monitoring systems and virtual vis-
its improve the quality of care while mini-
mizing direct and indirect healthcare costs
(18–20). Introduction of simple, reliable,
and sensitive objective measures to sup-
plement the in-office clinical evaluation
and extend it to a home environment has
the potential to enhance management of
Parkinson’s disease symptoms.
TECHNOLOGY HOLDS THE PROMISE OF
BETTER-INFORMED MEDICAL
DECISIONS DURING IN-CLINIC VISITS
A recent review by Maetzler et al. dis-
cussed details of several promising wear-
able technologies, including which para-
meters (motor and non-motor disabili-
ties) should be prioritized in assessment
strategies in Parkinson’s disease. There-
fore, a detailed review of different tech-
nologies and parameters is not included
in this manuscript. The review concludes
that the currently available technologies
have not yet found their way into rou-
tine clinical assessment. The authors expect
that in the near future, this is expected to
drastically change and such techniques will
help to overcome the drawbacks that are
inherent to single or multiple “snapshot”
assessments in current clinical practice and
clinically oriented research (21). Technol-
ogy holds the promise of better manage-
ment of complicated PD patients but it
is not expected to eliminate the need of
regular office visits during which patients,
caregivers, and physicians can interact
face-to-face.
THE CHANGING HEALTHCARE MARKET
LANDSCAPEWILL INCREASE THE NEED
FOR REMOTE MONITORING OF
PATIENTS
An increasing proportion of patients and
caregivers are connecting through their
smartphones and tablets to a variety of
resources to assist in their care. Insurers,
pharmaceutical companies, and healthcare
professionals are developing mobile apps
and wearable sensors represent to support
this need. In US, the shift toward “account-
able” care will lead to wider adoption of
remote monitoring solutions for chronic
conditions. Juniper care predicted that by
2016, three million patients would be mon-
itored remotely over cellular networks (22).
Aetna, LifeWise, United Health, and Kaiser
Permanente have included mobile apps as
part of their strategy to improve customers’
experience. Pfizer, Boehringer Ingelheim,
GlaxoSmithKline, and AstraZeneca have
already invested time and effort in creat-
ing digital health solutions. Analysts pre-
dict that remote health is one of the
fastest growing areas of Healthcare IT,
and it is expected to save $36B by 2018
globally (23).
The Department of Veterans Affairs
(VA) serves as an example of how govern-
ment can advance important healthcare IT
initiatives ahead of the private sector by its
recent announcement to support telehealth
by eliminating co-pays for patients taking
advantage of virtual consultations (24). On
the other end of the spectrum, healthcare
professionals are connected with devices
for a variety of uses and are already adopt-
ing and recommending apps to improve
quality of care. Almost 90% of physicians
would like their patients to monitor their
health independently. There are already 75
FDA-cleared apps from a total of 13,000
claimed medical mobile applications (22).
THE COST OF PORTABLE MEASURING
DEVICES IS DECREASING: THE
OPPORTUNITIES ARE THERE FOR THE
TAKING
Enhancing the application of available
treatments by leveraging rapidly growing
technologies in a complex healthcare land-
scape offers both challenges and opportu-
nities. Development of combined mobile
applications and wearable sensor systems
is an innovative concept that can have
immediate healthcare implications. Such
technologies could allow for remote moni-
toring/virtual visits, improved access, and
reduced cost while improving the over-
all experience, especially for patients with
chronic conditions. In a recent pilot clin-
ical study of “virtual house calls” for
Parkinson’s disease, remote visits saved par-
ticipants on average 100 miles, and 3 h of
travel (25). The development and valida-
tion of these tools takes a fraction of the
time and cost compared to traditional drug
development.
In conclusion, remote monitoring sys-
tems for Parkinson’s disease will support
the patient, the caregiver, and the health-
care professional in their collaborative
efforts for better care. Access is improved
and even patients in distant areas can have
their symptoms captured and transmit-
ted to specialists remotely. The wealth of
newly captured data in the natural eco-
logical environment of patients has the
capacity to enhance our understanding of a
patient’s status and tailor his/her treatment
according to specific motor function and
complication profiles. Technology-driven
optimization of therapy in Parkinson’s dis-
ease holds the promise of leading to faster
access to care and more effective outcomes
for individual patients while substantially
decreasing healthcare costs compared to
the current in-clinic visit model.
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